



Extraction of Non-Polar Basic Drugs from Plasma with Polymeric SPE Cation Exchange, Bond Elut™ Plexa™ PCX

William Hudson, Andrea Junker-Buchheit
Varian, Inc.

Introduction

Bioanalytical methods for pharmaceutical analysis require quick and easy method development and validation to reduce bottlenecks in drug development. Biological samples can be complicated to analyze due to proteins, peptides, salts, phospholipids and other endogenous compounds. Sample clean-up is necessary to remove these interferences without significant loss of the target analytes. Solid-phase extraction utilizing simplified methodologies for routine analysis are the techniques of choice.

Bond Elut™ Plexa™ PCX is a new addition to the Plexa family and uses a polymer cation exchange technique. Plexa PCX utilizes a generic and simplified method to remove neutral and acidic interferences from the matrix and concentrate basic analytes resulting in improved analytical performance and sensitivity in the quantitation of basic compounds. In addition, faster and highly reproducible flow rates are the norm, resulting in excellent tube-to-tube and well-to-well performance. Plexa PCX significantly reduces ion suppression because its highly polar, hydroxylated surface is entirely amide-free. The particle exterior excludes proteins and avoids strong binding of phospholipids. Thus, efficient removal of phospholipids from plasma is ensured. A simple generic method was developed for the extraction and analysis of non-polar basic compounds in human plasma.

Materials and Methods

Table 1: SPE Reagents and Solutions

A Bond Elut Plexa 10 mg 96 well plate (A4969010) has been used for the solid phase extraction of the target compounds.

2% Phosphoric acid	Add 20 µL of concentrated H ₃ PO ₄ to 1 mL of DI water
Methanol	Reagent grade or better
2% Formic acid	Add 20 µL of concentrated Formic acid to 1 mL of DI water
Methanol:acetonitrile (1:1, v/v)	Add 1 mL of methanol to 1 mL of acetonitrile
5% NH ₃ in methanol:acetonitrile (1:1, v/v)	Add 50 µL of concentrated ammonia to 1 mL of methanol:acetonitrile (1:1, v/v)

Table 2: Generic SPE Method

Sample pre-treatment	Spike 100 µL human plasma with basic drugs and internal standard. Then dilute 1:3 with 2% H ₃ PO ₄ .
Condition	1. 500 µL CH ₃ OH 2. 500 µL DI H ₂ O
Load	Sample containing basic drugs at a flow rate of 1 mL/min
Wash 1	500 µL 2% Formic acid
Wash 2	500 µL acetonitrile:methanol (1:1, v/v)
Elution	500 µL 5% NH ₃ methanol:acetonitrile

All samples are evaporated to dryness and reconstituted in 100 µL of 80:20 0.1% aq formic acid: CH₃OH. LC/MS is performed on a Varian 320-MS LC / Triple Quadrupole Mass Spectrometer.

LC Conditions

Mobile Phase: A: 0.1% Formic Acid
B: Methanol

Gradient: t = 0 min 80% A : 20% B
t = 0 - 2:0 min 20% A : 80% B
t = 3:30 - 5:0 min 80% A : 20% B


Column: Pursuit C18 3 µm 50 x 2.0 mm (A3051 050 X 020)

Table 3: MS conditions

Transition ions and collision energy were:

Compound	Q1	Q3	CE [V]
Ranitidine	315.0	176.0	-21.0
Propranolol	260.1	116.0	-17.5
Amitriptyline	278.1	233.0	-17.0
Loratadine	383.1	337.0	-31.0

Capillary Voltage at 25 V; Drying gas temperature at 400°C and 30 psi, CID = Argon, ESI: positive.



Chromatograms of a 50 ng/mL extract.

Results and Discussion

This LC/MS method describes the quantitative determination of non-polar basic compounds in human plasma using Bond Elut™ Plexa™ PCX for SPE. The Limit of Detection (LOD) of the solid phase extraction and LC/MS/MS analysis was 1.0 ng/mL. Recoveries were calculated from a 2nd order regression with RSD values based on a sampling of n = 6. Excellent recoveries were achieved, demonstrating good retention and elution, as well as minimal ion suppression. Response for all the compounds evaluated was linear up to 3 orders of magnitude from 1.0 ng/mL to 1.0 µg/mL with correlation coefficients all above 0.999. To demonstrate reproducibility, samples were analyzed at two different concentrations (n = 6). As shown in Table 4, reproducibly high recoveries were obtained according to the generic standard protocol.

Table 4: Recoveries of non-polar basic compounds from human plasma

Analyte	pKa	logP	% recovery ¹ (500 ng/mL)	% RSD ²	% recovery ¹ (1000 ng/mL)	% RSD ²
Ranitidine	8.2	1.90	101	5	94	6
Propranolol	9.5	3.60	97	7	92	4
Amitriptyline	9.4	4.60	95	5	91	5
Loratadine	9.3	5.20	100	4	91	4

¹Recoveries calculated as % of signal intensity of an extracted sample compared to that calibration curve. ²RSD = standard deviation/average recovery x 100; n = 6.

Conclusions

With Bond Elut Plexa PCX, it is possible to use a single method for the extraction of non-polar basic analytes from plasma that delivers reproducibly high recoveries. Under acidic conditions, the charged analyte binds to the cation-exchange groups of the sorbent (see Table 4 for pKa). Polar interferences and proteins are washed away with an acidic, aqueous solution. A neutral wash with relatively strong solvents, such as 50% methanol:acetonitrile, is possible without loss of analyte. The wash elutes neutral compounds retained in the hydrophobic cores of the sorbent. Finally, a mixture of organic solvents with ammonia is used to disrupt the cation exchange interaction, resulting in the elution of the basic drugs.

Flow rate over the 96-well plate is fast because Plexa PCX particles have much smaller interstitial paths with no fines to cause blockages, resulting in high well-to-well reproducibility. Automated 96-well technology is convenient which opens new opportunities to maximize efficiency. Bond Elut Plexa PCX is therefore a useful tool for high-throughput SPE applications which require analysis at low analyte levels, need validated reproducibility, and that must be quickly implemented with minimal method development. It is highly recommended for bioanalytical work in pharmaceutical clinical trials, including contract research.

These data represent typical results.
For further information, contact your local Varian Sales Office.

Bond Elut Plexa, Varian and the Varian Logo are trademarks of Varian, Inc.

© Varian, Inc. 2007

Varian, Inc.
www.varianinc.com
North America: 800.926.3000 – 925.939.2400
Europe: The Netherlands: 31.118.67.1000
Asia Pacific: Australia: 613.9560.7133
Latin America: Brazil: 55.11.3845.0444

